Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Current Deferred Revenue: 2016-2024

Historic Current Deferred Revenue for Rhythm Pharmaceuticals (RYTM) over the last 3 years, with Dec 2024 value amounting to $1.3 million.

  • Rhythm Pharmaceuticals' Current Deferred Revenue changed negligibly% to $1.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.3 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.3 million for FY2024, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q4 2024, Rhythm Pharmaceuticals' Current Deferred Revenue is $1.3 million, which was down 0.00% from $1.3 million recorded in Q3 2024.
  • In the past 5 years, Rhythm Pharmaceuticals' Current Deferred Revenue ranged from a high of $9.4 million in Q1 2022 and a low of $1.3 million during Q2 2023.
  • In the last 3 years, Rhythm Pharmaceuticals' Current Deferred Revenue had a median value of $1.3 million in 2024 and averaged $2.1 million.
  • Data for Rhythm Pharmaceuticals' Current Deferred Revenue shows a maximum YoY tumbled of 84.87% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Rhythm Pharmaceuticals' Current Deferred Revenue stood at $7.0 million in 2021, then crashed by 79.51% to $1.4 million in 2022, then decreased by 10.32% to $1.3 million in 2023, then remained steady at $1.3 million in 2024.
  • Its last three reported values are $1.3 million in Q4 2024, $1.3 million for Q3 2024, and $1.3 million during Q2 2024.